类风湿关节炎患者中多病共存与合并症的种族差异
该病例对照研究基于OptumLabs数据仓库2010至2019年数据,按年龄、性别、种族和族裔等1:1匹配154,391例类风湿关节炎患者与对照。类风湿关节炎患者多病共存(≥2或≥5种经验证的合并症)的校正比值比分别为2.19(95%CI 2.16-2.23)和2.06(95%CI 2.02-2.09),且各racially and ethnically组相似。黑人入组者多病共存≥2/≥5比例最高(73.1%、34.3%),亚裔最低(52.4%、17.3%)。
要点
- 类风湿关节炎患者多病共存≥2和≥5的校正OR分别为2.19(95%CI 2.16-2.23)和2.06(95%CI 2.02-2.09)。
- 黑人入组者多病共存≥2/≥5比例最高(73.1%、34.3%),亚裔最低(52.4%、17.3%)。
- 白人肾脏疾病(4.7% vs 3.2%)及黑人和白人瓣膜性心脏病(3.2%和2.8% vs 2.6%和2.2%)发生率升高(P<0.001)。
核心结论
- 多病共存是所有类风湿关节炎患者面临的问题。
- 按种族和族裔有针对性地识别某些合并症可能是减轻多病共存的有益方法。
研究设计与样本
- 基于OptumLabs数据仓库2010至2019年的病例对照研究。
- 类风湿关节炎病例定义为2个编码加处方一种类风湿关节炎药物,按年龄、性别、种族和族裔、地区、类风湿关节炎索引日期和保险覆盖时长1:1匹配非类风湿关节炎对照。
- 多病共存定义为存在≥2或≥5种经验证的合并症。
- 共识别154,391例类风湿关节炎病例和154,391例对照(平均年龄59.6岁,76%为女性)。
主要发现
- 黑人入组者多病共存≥2/≥5比例最高(73.1%、34.3%),亚裔入组者最低(52.4%、17.3%)。
- 类风湿关节炎病例相对于对照,多病共存≥2和≥5的校正比值比分别为2.19(95%CI 2.16-2.23)和2.06(95%CI 2.02-2.09)。
- 该增加在各racially and ethnically组间相似。
- 按种族和族裔与对照相比,某些合并症发生率升高(P<0.001),包括白人入组者肾脏疾病(4.7% vs 3.2%)以及黑人和白人入组者瓣膜性心脏病(3.2%和2.8% vs 2.6%和2.2%)。
关键数值与推荐
- 多病共存定义为≥2或≥5种经验证的合并症。
- 类风湿关节炎病例定义为2个编码加处方一种类风湿关节炎药物。
- 匹配变量包括年龄、性别、种族和族裔、地区、类风湿关节炎索引日期和保险覆盖时长。
临床怎么用
- 原文结论指出多病共存是所有类风湿关节炎患者面临的问题。
- 原文认为按种族和族裔有针对性地识别某些合并症可能是减轻多病共存的有益方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify differences in multimorbidity and individual comorbidities among individuals with rheumatoid arthritis (RA), separated by race and ethnicity. METHODS: This case-control study within OptumLabs Data Warehouse from 2010 to 2019 matched RA cases (defined by 2 codes plus prescription of an RA drug) to non-RA controls 1:1 on age, sex, race and ethnicity, region, index date of RA, and insurance coverage duration. We defined multimorbidity as the presence of ≥2 or ≥5 validated comorbidities. Logistic regression models calculated adjusted odds of multimorbidity with 95% confidence intervals (95% CIs) within each race and ethnicity. RESULTS: We identified 154,391 RA cases and 154,391 controls (mean age 59.6, 76% female). Black enrollees had the most multimorbidity ≥2/≥5 (73.1%, 34.3%); Asian enrollees had the least (52.4%, 17.3%). Adjusted odds of multimorbidity ≥2 and ≥5 in RA cases versus controls was 2.19 (95% CI 2.16-2.23) and 2.06 (95% CI 2.02-2.09), respectively. This increase was similar across race and ethnicity. However, we observed elevated occurrence of certain comorbidities by race and ethnicity versus controls (P < 0.001), including renal disease in White enrollees (4.7% versus 3.2%) and valvular heart disease in Black and White enrollees (3.2% and 2.8% versus 2.6% and 2.2%). CONCLUSION: Multimorbidity is a problem for all RA patients. Targeted identification of certain comorbidities by race and ethnicity may be a helpful approach to mitigate multimorbidity.
引用
- Kronzer VL, Dykhoff HJ, Stevens MA, et al. Racial Differences in Multimorbidity and Comorbidities in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022. PMID: 36094853. doi:10.1002/acr.25020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。